I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the groundbreaking news about AstraZeneca’s Imfinzi and Imjudo
What if a single drug could redefine survival chances for thousands facing lung cancer surgery in Europe? Imagine a patient, newly diagnosed with non-small cell lung cancer (NSCLC), grappling with the uncertainty of whether their tumor can be removed and if they’ll face recurrence. For many, this
Imagine waking up each day to find more hair on your pillow than on your scalp, a stark reminder of an unseen battle within your body that strips away confidence. Alopecia areata (AA), an autoimmune condition, affects nearly 700,000 individuals in the United States, causing unpredictable hair loss
What happens when a disease as merciless as amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), strikes a tiny fraction of patients with a genetic twist that makes it even deadlier? For the roughly 2% of ALS sufferers with mutations in the SOD1 gene, life has often felt
What if a single monthly infusion could halt the heartbreaking decline of memory and independence for millions of Europeans with early Alzheimer’s disease, bringing hope to families across the continent? This question, once a distant dream, now edges closer to reality with donanemab, a pioneering
In the complex world of oncology, multiple myeloma (MM) stands as a formidable challenge, affecting thousands across Europe with its intricate disease mechanisms and diverse patient needs. As the second most common blood cancer after non-Hodgkin lymphoma, MM impacts around 46,000 new individuals
